Designed for Children

Sialanar® is licensed for the symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders.1

Sialanar® (400mcg/ml glycopyrronium bromide equivalent to 320mcg/ml glycopyrronium)

Designed for Children

Tailored titration for flexible and accurate dosing1

60% less volume vs. 1mg/5ml glycopyrronium bromide oral solutions, helping to improve patient acceptability and tolerability1-5

Minimal excipients to reduce toxicity risk - sugar, alcohol and sorbitol free1,7,8

Use the links below to explore

Sign up for Proveca Education Events

Proveca run educational sessions on a regular basis covering a variety of topics, register here to be the first to know what’s coming up or head to our resources section to catch up on previous sessions.

References

  1. Sialanar® SmPC (January 2023) https://www.medicines.org.uk/emc/product/2301 – accessed August 2023 
  2. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Colonis Pharma) SmPC (September 2021) https://www.medicines.org.uk/emc/product/7344/smpc#gref - accessed August 2023 
  3. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Rosemont Pharmaceuticals Limited) SmPC (December 2021) https://www.medicines.org.uk/emc/product/13136/smpc – accessed August 2023 
  4. Glycopyrronium Bromide 1 mg/5 ml Oral Solution (Strandhaven Limited t/a Somex Pharma UK Limited) SmPC (July 2022) https://www.medicines.org.uk/emc/product/14104/smpc – accessed August 2023 
  5. Batchelor H & Marriot J. BJCP 2015. Formulations for Children: Problems and Solutions https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.12268 - accessed August 2023
  6. NPPG Positioning statement 2020-21 available at http://nppg.org.uk/choosing-an-oral-liquid-for-a-child/ - accessed August 2023 
  7. Rouaz K, et al. Excipients in the paediatric population: a review. Pharmaceutics 2021; 13(3): 387.
  8. Arthur S. How to identify and manage ‘problem’ excipients in medicines for children. The Pharmaceutical Journal 2017. Available at:https://pharmaceutical-journal.com/article/ld/how-to-identify-and-manage-problem-excipients-in-medicines-for-children – accessed August 2023
  9. Parr J.R, Todhunter E, Pennington L, et al. Drooling Reduction Intervention randomized trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2017; 1-6. Doi:10. 1136/ archdischild-2017-313763.
  10. Reid S.M, et al. Anticholinergic medications for reducing drooling in children with developmental disability. Developmental Medicine & Child Neurology 2019; 63(3): 346-353
  11. Reddihough, D et al. J of Paediatr and Child Health 2021, 37: 183-186

UK-SIA-23-0108 | August 2023

Reporting of side effects

UK
If you/your child experience(s) any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. 

Republic of Ireland
If you/your child experience(s) any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Adverse event should be reported, reporting forms and information can be found at: www.hpra.ie.

By reporting side effects, you can help provide more information on the safety of this medicine.

Side effects should also be reported to Proveca Limited.
Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com

You are now leaving a Proveca website.

Proveca are not responsible for the content on this website.

Continue

This website is for UK and ROI Healthcare Professionals

By entering this site, you are confirming that you are a UK or ROI Healthcare Professional. This site contains promotional information.

I am a UK or ROI Healthcare Professional I am a patient or parent/carer of a patient prescribed Sialanar in the UK or ROI I am a member of the public
UK-SIA-23-0102 | August 2023